Therapeutic siRNA: State-of-the-Art and Future Perspectives.
- Published in:
- BioDrugs, 2022, v. 36, n. 5, p. 549, doi. 10.1007/s40259-022-00549-3
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2022 AND VI 36 AND IP 5
Results: 9
1
2
Teserpaturev/G47Δ: First Approval.
- Published in:
- BioDrugs, 2022, v. 36, n. 5, p. 667, doi. 10.1007/s40259-022-00553-7
- By:
- Publication type:
- Article
3
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
- Published in:
- BioDrugs, 2022, v. 36, n. 5, p. 609, doi. 10.1007/s40259-022-00551-9
- By:
- Publication type:
- Article
4
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis.
- Published in:
- BioDrugs, 2022, v. 36, n. 5, p. 591, doi. 10.1007/s40259-022-00550-w
- By:
- Publication type:
- Article
5
The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease.
- Published in:
- BioDrugs, 2022, v. 36, n. 5, p. 639, doi. 10.1007/s40259-022-00548-4
- By:
- Publication type:
- Article
6
Real-World Effects of Biologics on Renal Function in Psoriatic Patients: A Retrospective Study.
- Published in:
- BioDrugs, 2022, v. 36, n. 5, p. 657, doi. 10.1007/s40259-022-00547-5
- By:
- Publication type:
- Article
7
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.
- Published in:
- BioDrugs, 2022, v. 36, n. 5, p. 625, doi. 10.1007/s40259-022-00546-6
- By:
- Publication type:
- Article
8
Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
- Published in:
- BioDrugs, 2022, v. 36, n. 5, p. 645, doi. 10.1007/s40259-022-00545-7
- By:
- Publication type:
- Article
9
Plant-Derived Human Vaccines: Recent Developments.
- Published in:
- BioDrugs, 2022, v. 36, n. 5, p. 573, doi. 10.1007/s40259-022-00544-8
- By:
- Publication type:
- Article